AU2012347595A1 - Oral formulations for treating metal overload - Google Patents

Oral formulations for treating metal overload Download PDF

Info

Publication number
AU2012347595A1
AU2012347595A1 AU2012347595A AU2012347595A AU2012347595A1 AU 2012347595 A1 AU2012347595 A1 AU 2012347595A1 AU 2012347595 A AU2012347595 A AU 2012347595A AU 2012347595 A AU2012347595 A AU 2012347595A AU 2012347595 A1 AU2012347595 A1 AU 2012347595A1
Authority
AU
Australia
Prior art keywords
compound
dosage form
solid dosage
formula
oral formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012347595A
Other languages
English (en)
Inventor
Hugh Y. Rienhoff Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FerroKin BioScience Inc
Original Assignee
FerroKin BioScience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48574916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012347595(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by FerroKin BioScience Inc filed Critical FerroKin BioScience Inc
Publication of AU2012347595A1 publication Critical patent/AU2012347595A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2012347595A 2011-12-09 2012-12-07 Oral formulations for treating metal overload Abandoned AU2012347595A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568914P 2011-12-09 2011-12-09
US201161568890P 2011-12-09 2011-12-09
US61/568,890 2011-12-09
US61/568,914 2011-12-09
PCT/US2012/068432 WO2013086312A1 (en) 2011-12-09 2012-12-07 Oral formulations for treating metal overload

Publications (1)

Publication Number Publication Date
AU2012347595A1 true AU2012347595A1 (en) 2014-06-26

Family

ID=48574916

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012347595A Abandoned AU2012347595A1 (en) 2011-12-09 2012-12-07 Oral formulations for treating metal overload

Country Status (9)

Country Link
US (1) US8993606B2 (cg-RX-API-DMAC7.html)
EP (1) EP2787994A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015500294A (cg-RX-API-DMAC7.html)
AR (1) AR089122A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012347595A1 (cg-RX-API-DMAC7.html)
BR (1) BR112014013985A2 (cg-RX-API-DMAC7.html)
CA (1) CA2857990A1 (cg-RX-API-DMAC7.html)
TW (1) TW201338777A (cg-RX-API-DMAC7.html)
WO (1) WO2013086312A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140343110A1 (en) 2011-12-16 2014-11-20 University Of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
EP2970162A1 (en) 2013-03-15 2016-01-20 Ferrokin Biosciences, Inc. Polymorph forms of desazadesferrithiocin analogs
AU2014352780A1 (en) * 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
WO2018104130A1 (en) 2016-12-07 2018-06-14 Lumileds Holding B.V. Flash light emitter with remote communication function
CN114302882A (zh) * 2019-07-19 2022-04-08 威佛（国际）股份公司 用于治疗输血依赖型β-地中海贫血（tdt）的膜铁转运蛋白抑制剂
WO2022157185A1 (en) 2021-01-20 2022-07-28 Vifor (International) Ag Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1866296T3 (pl) 2005-04-04 2017-05-31 University Of Florida Research Foundation, Inc. Polieterowe analogi desferritiocyny
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8324397B2 (en) 2007-03-15 2012-12-04 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
NZ605452A (en) * 2008-07-14 2014-05-30 Ferrokin Biosciences Inc Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents
BR112012001761A2 (pt) 2009-07-27 2017-05-09 Ferrokin Bioscience Inc composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo
WO2011028255A2 (en) 2009-08-25 2011-03-10 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues and uses thereof
US9045440B2 (en) 2010-05-04 2015-06-02 Ferrokin Biosciences, Inc. Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents

Also Published As

Publication number Publication date
CA2857990A1 (en) 2013-06-13
US20130225645A1 (en) 2013-08-29
US8993606B2 (en) 2015-03-31
JP2015500294A (ja) 2015-01-05
TW201338777A (zh) 2013-10-01
EP2787994A4 (en) 2015-08-26
EP2787994A1 (en) 2014-10-15
WO2013086312A1 (en) 2013-06-13
BR112014013985A2 (pt) 2017-06-13
AR089122A1 (es) 2014-07-30

Similar Documents

Publication Publication Date Title
US8993606B2 (en) Oral formulations for treating metal overload
KR101888713B1 (ko) 페노티아진 디아미늄 염 및 이의 용도
US20070259930A1 (en) Compositions and methods of using r(+) pramipexole
KR102528435B1 (ko) 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물
US9012484B2 (en) Crystal and pharmaceutical preparation containing the same crystal
KR20120115380A (ko) 마이봄선 기능 장애의 치료 방법
TWI884912B (zh) 喹啉酮類似物及其鹽、組合物及其使用方法
JP2015500294A5 (cg-RX-API-DMAC7.html)
US10501423B2 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
KR20200141446A (ko) 감소된 3급-부탄올 수준을 갖는 약제학적 조성물
KR101061764B1 (ko) 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP3089740A1 (en) Pharmaceutical composition
CN105636583B (zh) 水溶液制剂及其制造方法
JP6907174B2 (ja) アミロイド線維形成の抑制又は阻害剤
US20250268979A1 (en) Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
US20150299151A1 (en) Polymorph forms of desazadesferrithiocin analogs
US9512095B2 (en) Polymorph forms of desazadesferrithiocin analogs
CN107648195A (zh) 稳定的非布司他胶囊剂药物组合物
WO2022140646A1 (en) Dosing regimen for oteseconazole
EP4011899A1 (en) Deoxycholic acid compounds, pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period